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Age-related depletion of estrogens and androgens is associated with an increase in Alzheimer’s
disease (AD) brain pathology and diminished cognitive function. Here we investigated AD-asso-
ciatedmolecular and cellular changes in brains of aged hypogonadal (hpg) male and femalemice.
hpg Mice have a spontaneous, inactivating genetic mutation in the GnRH gene resulting in life-
long deficiency of gonadotropins and gonadal sex hormones. Western blot analysis revealed low
levels of amyloid precursor protein and high levels of presenilin 1, amyloid precursor protein
C-terminal fragment, and -amyloid 42 in brains of agedmale, but not female, hpgmice. Changes
were confined to the hippocampus and were not evident in the cerebellum or other brain tissues.
Male hpgmice tended to have lower levels of IL-1 protein than male littermate controls. Immu-
nohistochemical staining of the basal forebrain revealed that male hpg mice had lower choline
acetyltransferase levels perneuron comparedwith controls. TheseAD-like changes specific tomale
hpg mice supports a link between androgen depletion and the development of AD pathology.
(Endocrinology 153: 2789–2799, 2012)
Age-related decline in circulating sex hormones has di-verse effects on virtually all tissues. In the brain, low
levels of circulating sex hormones have been linked to
decreased cognitive function in males and females (1–4),
as well as increased neurodegeneration (5–7). Low levels
of endogenous sex hormones may also be a risk factor for
Alzheimer’s disease (AD) in both males and females (8–
10). Men with AD are more likely to have lower levels of
circulating andbrain testosterone than cognitively normal
age-matched controls (11–13). Likewise, femaleswithAD
also have lower levels of circulating and brain estradiol
than cognitively normal age-matched controls (10, 14).
The two main pathological hallmarks of AD are senile
plaques and neurofibrillary tangles, which are primarily
composed of -amyloid (A) and hyperphosphorylated ,
respectively. A is produced by amyloidogenic processing
of amyloid precursor protein (APP). APP is initially
cleaved by-site APP cleaving enzyme (BACE) to produce
APP-C-terminal fragment (APP-CTF), which is then
cleaved by -secretase to produce A of various lengths,
A40 and A42 being the most common forms (reviewed
in Ref. 15). Chemical depletion of gonadal hormones in
men being treated for prostate cancer results in increased
plasma A levels (16). Animal studies have also shown
that depletion of androgens results in increased A (17–
19) and that testosterone is protective against hyperphos-
phorylated  in vivo (20). Similarly, depletion of estrogens
also results in increased A in some (21–23) but not all
studies (24–27). Overall, these results suggest that deple-
tionof sexhormonesmay result in increasedAD-likebrain
pathology, which could provide the link behind the in-
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creased risk for AD and reduced levels of circulating sex
hormones.
Determining the specific effects of individual sex hor-
mones in the brain is difficult using pharmacological
means due to the closed-loop negative-feedback mecha-
nisms operating the hypothalamic-pituitary-gonadal axis
that produce confounding reflex effects to administration
of exogenous steroids. The alternative of anopen loop (i.e.
castration) can only be achieved postnatally and may in-
volve nonphysiological patterns of hormone delivery.
Most neuroscience researchhas examined thebrain effects
of sex hormone depletion using gonadectomized (GDX)
animals with or without administration of exogenous sex
steroids. Interpreting these studies is influenced by sys-
tematic design differences including the age at GDX and
mode of hormone delivery. An alternative to pharmaco-
logical methods to evaluate sex steroid effects is the use of
genetic animal models to eliminate sex steroid effects.
This study used the hypogonadal (hpg)mousemodel as
an alternative to GDX animals to examine the effects of
life-long sex steroid depletion. These mice have a sponta-
neous, inactivating genetic mutation involving a major
deletion (28) in theGnRH1 gene, preventing GnRH pro-
duction and resulting in lifelong reproductive immaturity
with low blood levels of gonadotropins (29, 30) and go-
nadal sex steroids (31). Although extensively studied to
examine reproductive function (32), to date there has been
little focus on age-related morphological or molecular
changes in the brains of these animals with lifelong deficit
of reproductive hormones. Thus the focus of this study
was to determine the effect of lifelong reproductive hor-
mone depletion on certain molecular pathways involved
inAD including amyloidogenic processingofAPP, choline
acetyltransferase (ChAT) expression, and mediators of
neuroinflammation. Specific brain regions such as the hip-
pocampus are primarily affected in AD, whereas other
brain regions such as the cerebellum are comparatively
spared; therefore, molecular changes associated with AD
were examined in both of these regions of aged animals of
both genders.
Materials and Methods
Animals
Both hpg and background (C3H/J) wild-type littermate mice
were obtained from the ANZAC Research Institute in Sydney,
Australia and genotyped as described previously (33). The age of
hpg and wild-type mice when euthanized ranged from 12–19
months (Table 1). Of the 34mice used, 31were aged between 17
and 19 months. Only three mice, which were all hpgmale mice,
were killed at 12months of age. All animal experimentationwas
approved by theAnimalWelfareCommittee of the Sydney South
WestAreaHealthService aswell as theAnimalEthicsCommittee
of theUniversityofWesternAustralia andconformed tonational
guidelines for animal experimentation.
Antibodies
The APP monoclonal antibody C1/1.6, directed against the
last 20 residues of APP, was used to detect full-length APP and
APP-CTF (gift from Dr. Paul Mathews, Nathan Kline Institute,
New York, NY). Presenilin 1 (PS1) was detected using antibody
14, a rabbit polyclonal antiserum specific for amino acids 3–15
of PS1 (gift from Professor SamGandy, Nathan Kline Institute).
Mouse APP/A was detected using the Rb194 rabbit antiserum
specific for amino acids 3–16 of mouse A (gift fromDr. Pankaj
Mehta, NewYork State Institute for Basic Research, NewYork,
NY). Antibodies against glial fibrillary acidic protein (GFAP)
(Sigma Chemical Co., St. Louis, MO), ChAT (Chemicon, Te-
mecula,CA), P450 side-chain cleavage (P450scc;Chemicon) and
apolipoprotein E (apoE;Millipore Corp., Bedford,MA)were all
commercially purchased.
Tissue processing
Mice were separated into two groups, one for immunohisto-
chemistry andmorphological analysis and one for protein quan-
tificationusingWesternblot, ELISA, andLuminex (Table 1). For
immunohistochemistry and morphological analysis, mice were
deeply anesthetized with sodium pentobarbitone (ip) and per-
fused with PBS containing 0.1% heparin followed by 4% para-
formaldehyde in Sorenson’s phosphate buffer solution (pH 7.4).
Brains were removed and postfixed overnight at 4 C in 4%para-
formaldehyde and embedded in paraffin. Serial 10-m coronal
sections were cut using a microtome and collected onto glass
slides (Superfrost Plus; Menzel Glaser, Singapore), with each
series consisting of 10 slides and each slide containing sections
that were 200 m apart.
For protein analysis, micewere euthanized via an overdose of
sodiumpentobarbitone (ip).Brainswere removed, snap frozen in
liquid nitrogen, and stored at 80 C until further use. Brains
TABLE 1. Numbers and ages of mice in each experimental group
Western blot/ELISA/Luminex Immunohistochemistry
n Average age (age range) n Average age (age range)
hpg male 6 15 months (12–17 months) 4 15 months (12–17 months)
Wild-type male 5 All 17 months 3 All 17 months
hpg female 6 18.5 months (17–19 months) 4 18.5 months (18–19 months)
Wild-type female 4 17.5 months (17–18 months) 2 18 months (17–19 months)
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were divided into two hemispheres: one forWestern blot and the
other for ELISA/Luminex.
Periodic-acid Schiff (PAS) staining and
immunohistochemistry
Hippocampal morphology and glycogen-rich regions were
observed in sections stained with the PAS stain and counter-
stained with hematoxylin. APP and GFAP protein localization
was determined by fluorescent immunohistochemistry. Briefly,
paraffin sections were dewaxed and rehydrated. Sections then
underwent antigen retrieval by microwave boiling in 10 mM ci-
trate buffer (pH 6) followed by successive washes in PBS, 80mM
NH4Cl (pH7.4), andPBS for 10min each. Sectionswere blocked
with blocking buffer (PBS; 10% normal goat serum; 0.2% Tri-
ton-X100) for 1 h at room temperature and incubated overnight
(4 C) with primary antibodies against APP (Rb194; 1:500) and
GFAP (1:500) diluted in blocking buffer. Sections were washed
with PBS, incubated with antimouse fluorescein isothiocyante
(1:100; ICN Cappel, Costa Mesa, CA) and antirabbit Cy3 (1:
300; Jackson ImmunoResearch Laboratories, West Grove, PA)
secondary antibodies diluted in blocking buffer for 2 h at room
temperature, counterstained with Hoechst 33342 (Sigma; 4
l/ml in PBS), and coverslippedwithDako fluorescentmounting
media (DAKO Corp., Carpenteria, CA). Images were collected
using a multiphoton laser scanning confocal microscope.
Peroxidase immunohistochemistry for P450scc and ChAT
was performed. Sections were dewaxed and rehydrated and un-
derwent antigen retrieval using themethoddescribed above. Sec-
tions were blocked with 0.3% H2O2 in methanol for P450scc
immunohistochemistry and 2% H2O2 in PBS for ChAT immu-
nohistochemistry, each for20minat roomtemperature. Sections
were incubated in blocking buffers individually optimized for
P450scc (PBS; 5% normal goat serum; 3% skim milk; 0.5%
Triton-X100) and ChAT (PBS; 10% horse serum; 0.2% Triton-
X100) for 2 h and 1 h, respectively. Sectionswere incubatedwith
primary antibodies against P450scc (1:100) and ChAT (1:200)
overnight at 4 C. Sections were washed with PBS and incubated
with biotinylated secondary antibodies (1:800; Vector Labora-
tories, Inc., Burlingame, CA) for 2 h at room temperature. Sec-
tionswerewashedwith PBS and incubatedwith an avidin/horse-
radish peroxidase solution (Vectastain Elite ABC kit, diluted
1:100) for 1 h at room temperature. After further washes in PBS,
sections were incubated in metal enhanced 3,3-diaminobenzi-
dine substrate (Pierce Chemical Co., Rockford, IL) and cover-
slipped with DPX mounting media.
Western blot
Levels ofAPP,GFAP, apoE, PS1, andAPP-CTFproteinswere
measured in the hippocampus, cerebellum, and the rest of the
brain usingWestern blot. Individual brain regions were homog-
enized in buffer (PBS; 100 mM butylated hydroxytoluene;
100 mM EDTA), and total protein levels were determined. Sam-
ples were added to sodium dodecyl sulfate loading buffer (166
mM Tris-HCl, 8% sodium dodecyl sulfate, 4% glycine, 2.5%
2-mercaptoethanol, pinch of phenol red, pH 6.8), boiled at 95 C
for 10 min and loaded onto Tris-trycine polyacrylamide gels.
Proteins were separated using electrophoresis and transferred to
nitrocellulose membranes at 250 mA overnight at 4 C. Mem-
branes were blocked with 5% skim milk in Tris-buffered saline
for 1 h at room temperature and immunoblotted for APP/APP-
CTF (C1/1.6; 1:5,000), GFAP (1:10,000), apoE (1:10,000), and
PS1 (antibody 14; 1:2,000). Membranes were then incubated
with antimouse (1:5,000; GE Healthcare, Piscataway, NJ), an-
tigoat (1:10,000; Dako) or antirabbit (1:5,000; GE Healthcare)
horseradish peroxidase-conjugated secondary antibodies. Pro-
tein bands were detected using enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ) and developed onto
film. Membranes were stripped (Restore plus Western blotting
stripping buffer; Thermo Scientific, Rockford, IL) and probed
for -actin (1:10,000; Abcam, Cambridge, MA) to check for
equal protein loading. Films were scanned using a visual light
scanner, and intensity for eachproteinwas analyzedusingQuan-
tity One 1-D Analysis Software (Bio-Rad Laboratories, Inc.,
Hercules,CA).All sampleswere performed induplicate, andhpg
protein levels were normalized to wild-type levels for statistical
analysis.
A ELISA
A40 and A42 levels were quantified in the whole-brain
hemisphere using ELISA as previously described (34). ELISA
plateswere coatedwith the capture antibody6E10 (1:400; Signet
Diagnostic, Hicksville, NY), and detection antibodies against
A40 and A42 were donated by Dr. PankajMehta (NewYork
State Institute for Basic Research) . The optical density wasmea-
sured at 450 nm using a FLUOstar OPTIMA multifunction mi-
croplate reader. All samples were run in duplicate.
Because other molecular changes were only observed in the
hippocampus ofmale hpgmice, A40 andA42 levels were also
quantified in the hippocampus of additional male hpg (n  7)
andwild-typemice (n 7) aged 12months.Hippocampal A40
andA42 levelsweremeasured using high-sensitivity ELISAkits
(Wako Chemicals USA, Richmond, VA) according to manufac-
turer’s instructions, and all samples were run in duplicate.
Luminex
The concentration of IL-1 and IL-6 protein in the brain was
measured using Luminex. Proteinwas extracted from thewhole-
brain hemisphere using the same technique as for the A ELISA.
The assay was performed according to the manufacturer’s in-
structions for the Lincoplex kit (Linco Research, Inc., St.
Charles, MO; catalog no. MCYTO-70K).
Statistical analysis
Statistical analysis was performed using SPSS (Version 17).
When directly comparing two groups, two-tailed independent t
tests were performed. When comparing more than two groups,
univariateANOVAwasperformed.Levene’s testwasperformed
to test the equality of variance assumption for ANOVA. The
intensity of ChAT immunostaining was ranked on an ordinal
scale of 1–5, and the non-parametric Kruskal-Wallis test was
used to perform statistics to determine whether there was a sig-
nificant difference in the intensity of ChAT staining between hpg
and wild-type mice.
Results
Hippocampal morphology
The morphology of the hippocampus was examined in
PAS-stained sections and was found to be similar in hpg
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and wild-type mice. Individual hippocampal subregions
were qualitatively examined todeterminewhether specific
hippocampal cell populations were affected in hpg mice.
The area and width of the pyramidal cell layer of Amon’s
horn (including CA1–3) and the granule cell layer of the
dentate gyrus was examined using ImageJ (National In-
stitutes of Health, Bethesda, MD) in three randomly se-
lected coronal sections per brain ranging from 1.9 to
2.3mmfromBregma, each200mapart.Therewereno
gross differences observed in the area or width of the py-
ramidal or granule cell layers between hpg and wild-type
mice of either gender.
Neurosteroidogenesis
Although it is well known that circulating sex steroid
levels are low in hpg mice, neurosteroidogenesis has not
been previously examined in hpgmouse brains. Therefore
the level of P450scc, one of the rate-limiting factors for
steroidogenesis (35), was examined in the caudal hip-
pocampus and cerebellum, both regions previously shown
to be associated with high levels of neurosteroidogenesis
(36).Whereas femalemice had increased P450scc staining
compared with male mice in both brain regions, the level
of P450scc stainingwas not consistently different between
hpg and wild-type mice of either gender (Fig. 1). Females
had more P450scc in all regions examined, including the
hippocampus, cerebellum,medulla, andmidbrain (Fig. 1).
These gender differences were particularly obvious in the
cerebellum,with a subset of Purkinje cells stainingpositive
for P450scc in female brains, but not in male brains.
Levels of proteins associated with -amyloid
production
A consistent finding was that the brains of hpg male
mice contained significantly different levels of proteins
involved in amyloidogenicAPPprocessing comparedwith
malewild-typemice, including full-lengthAPP,APP-CTF,
and PS1, an integral component of -secretase. Male hpg
mice had significantly lower levels ofAPP (t test;P0.05)
and significantly higher levels of APP-CTF (t test; P 
0.01) and PS1 (t test; P 0.05) in the hippocampus than
male wild-type mice (Fig. 2). In contrast, protein levels of
APP, APP-CTF, and PS1 in the cerebellum and rest of the
brain were not significantly different between male hpg
and male wild-type mice. Immunohistochemistry was
used to determine the cellular location of APP in the hip-
pocampus. Hpg and wild-type mice had similar APP cel-
lular localization,with immunopositive stainingprimarily
observed throughout the soma of neurons inAmon’s horn
regions and the dentate gyrus, similar to previous studies
(37). A small proportion of immunopositive staining was
also observed in astrocytes and in the nuclei of some cells
(data not shown). Importantly, although there was some
variation in the age of male hpg mice at the time of eu-
thanasia (12–19 months), there was no relationship ob-
served between age and levels of theseAD-related proteins
FIG. 1. P450scc immunohistochemistry in the hippocampus (A–D) and cerebellum (E–H). P450scc expression was higher in the female brain than
in the male brain in both brain regions, regardless of whether it was from hpg or wild-type mice. Expression was particularly high in the female
cerebellum (G and H) with positive staining observed in Purkinje cells (arrows in G and H) that was absent in the male cerebellum (E and F). Scale
bar, 100 m
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measuredusing eitherWesternblot or immunohistochem-
istry; therefore all mice were included in the analysis.
Changes in the total level of APP, APP-CTF, and PS1
proteins in the male hpg hippocampus could suggest an
increase in amyloidogenic processing.To test this, levels of
A40 andA42were initiallymeasured in the entire brain
hemisphere using ELISA. There was no difference in the
amount ofA40orA42betweenhpg andwild-typemice
of either gender (ANOVA; Fig. 3, A and B). Because the
differences in APP, APP-CTF, and PS1 protein levels were
specifically observed in the hippocampus and not in other
brain regions, it was hypothesized that increasedA levels
may only be observed in the hippocampus. Therefore,
A40 and A42 protein levels were measured specifically
in the hippocampus of additional agedmale hpg andwild-
type mice. It was found that male hpg mice had signifi-
cantly higher A42 levels in the hippocampus than male
wild-type mice (t test; P 0.05; Fig. 3D). Although male
hpgmice also had higher A40 protein
levels in the hippocampus than male
wild-type mice, this difference was not
significant (t test; P  0.113; Fig. 3C).
These data therefore suggest that male
hpg mice had increased amyloidogenic
processing of APP that resulted in in-
creased expression of A42 specifically
in the hippocampus and not in other
brain regions.
In contrast to male mice, there was
no difference in the amount of proteins
related to amyloidogenic processing of
APP between female hpg and wild-type
mice. Western blot analysis showed no
significant difference in the amount of
APP, APP-CTF, or PS1 in the hip-
pocampus, cerebellum, or rest of the
brain between female hpg and wild-
type mice (Fig. 2). There was also no
difference in the amount of A40 or
A42 in the whole-brain hemisphere
between female hpg andwild-typemice
(Fig. 3, A and B).
Immunohistochemistry for APP re-
vealed areas in all brains that were in-
tensely stained forAPP (Fig 4, A andB).
These intensely stained areas had a
whorl-like appearance and hence are
referred to as “whorls” from here on.
Interestingly, whorls were only ob-
served in the thalamus and not in any
other brain regions. When APP immu-
nohistochemistry was costained with
GFAP and Hoechst 33342, it was found that whorls con-
tained only APP, whereas GFAP-positive processes sur-
rounded the central whorl. Whorls were also positive for
PAS staining (Fig 4, C and D). PAS staining primarily
stains glycogen-rich regions but has also been shown to
stain amyloid deposits (38, 39). The total number of
whorls was counted across three coronal sections per
brain that were 200 m apart through the hippocampus.
The size of each of the whorls was also calculated, and it
was found that the number and size of the whorls were
similar in all animal groups, regardless of gender or de-
pletion of sex hormones.
ChAT protein
ChAT is an enzyme involved in the production of ace-
tylcholine and is depleted in AD (40); thus ChAT expres-
sion in hpgmice was assessed using immunohistochemis-
try. In all brains, ChAT-positive cells were found within
FIG. 2. Western blot analysis of protein expression of APP, PS1, and APP-CTF in the
hippocampus (HIPP), cerebellum (CB), and rest of the brain (ROB) in male and female hpg
mice. Representative blots for each protein are shown in panel A. Graphs show average
density of hpg protein bands normalized to wild-type (WT) levels, depicted by the dashed line
at 100%. Male hpg protein levels shown in graphs B–D and female hpg protein levels shown
in graphs E–G. The normalization to WT protein levels allows data to be presented as the
average protein levels from two duplicated Western blots that were performed to ensure
consistency. -Actin was used as the loading control. Data are shown as mean  SEM.
*, P  0.05; **, P  0.01 vs. WT protein level.
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the caudate/putamen and in the basal forebrain (including
the medial and lateral septal nuclei, substansia innomi-
nata, and the nucleus of the diagonal band of Broca). The
total number of ChAT-positive cells was counted across a
series of six 10-m sections, each 300 m apart per ani-
mal, between 1.24 mm and 0.65 mm from Bregma.
Cells were divided into two groups: those in the caudate/
putamen and those in the basal forebrain, and the total
number ofChAT-positive cellswas counted in each region
(Fig. 5, E and F). The number of ChAT-positive cells was
not affected in either region by gender or depletion of sex
hormones.However, the amountofChATstaining in each
individual cell was qualitatively different in hpg andwild-
type mice. The staining intensity of ChAT-positive cells
was graded on an ordinal scale of 1–5 (1, faint immuno-
staining; 5, intense immunostaining) in five sections per
animal. Although there was occasional variability of
ChATstainingbetween sections fromeach animal, overall
it was found that ChAT staining was less intense in sec-
tions from male hpgmice in comparison with those from
malewild-typemice (Kruskal-Wallis;P 0.05), and there
was no apparent difference in the amount of ChAT stain-
ing between female hpg and wild-type mice. Representa-
tive images of ChAT intracellular staining intensity are
shown in Fig. 5. There was also a gender difference in the
staining pattern in ChAT-positive cells regardless of sex
hormone depletion; male ChAT positive cells had a
rounder shape and more consistent staining throughout
the cytoplasm, whereas female cells were smaller and less
round, and cytoplasmic staining was more granular.
Inflammatory and other changes
There was no significant difference in the amount of
GFAPproteinbetweenmalehpgandwild-typemice in any
brain region measured using Western blot (data not
shown). In contrast, female hpg mice had significantly
lower total GFAP protein in the cerebellum than female
wild-type mice (t test; P  0.01), but this effect was not
observed in the hippocampus or rest of the brain. GFAP
expression was also examined in the hippocampus using
immunohistochemistry, but therewerenoconsistentlyob-
servable differences between hpg and wild-type mice or
between male and female mice. ApoE protein levels were
also examined using Western blot but there was no sig-
nificant difference in the amount of apoEbetweenhpg and
wild-type mice in any brain region, in either gender (data
not shown).
Inflammation is a key pathological feature of AD (for
review see Ref. 41). To test whether hpg mouse brains
were in a heightened inflammatory state, IL-1 and IL-6
were measured in the whole-brain hemisphere using Lu-
FIG. 4. APP immunopositive deposits in male (A and C) and female (B
and D) hpg brains. A and B show concentrated areas of APP
immunopositive staining (red) that were surrounded by GFAP
immunopositive astrocytes (green). Sections were also counterstained
with Hoechst to label nuclei (blue). These deposits were also PAS stain
positive (C and D). Scale bar, 50 m
FIG. 3. A40 and A42 levels in the whole-brain hemisphere (A and
B) and hippocampus (C and D) of hpg mice measured using ELISA. A
levels in the whole-brain hemisphere were normalized to the wild-type
(wt) male and female levels that are depicted as dashed line at 100%.
A levels in the hippocampus were only measured in male hpg and wt
mice. Data are shown as mean  SEM; *, P  0.05
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minex. There was a strong trend for brains frommale hpg
mice to have less IL-1 protein than brains from male
wild-type mice (t test; P 0.057; Fig. 6A).Male hpgmice
also had less IL-6 on average, but this was not statistically
significant due to high interanimal variation in the male
wild-type animals (Fig. 6B).Again, therewasnodifference
in levels of either IL-1or IL-6between the femalehpgand
wild-type mice.
Discussion
The lifelong lack of sex hormones resulted in gender-spe-
cific changes, with male hpgmice exhibiting a number of
AD-like changes including altered lev-
els of APP, APP-CTF, PS1, and A42
proteins in the hippocampus, decreased
ChAT immunoreactivity per neuron in
the basal forebrain, and a trend for
lower IL-1 levels. In contrast, the only
significant differenceobservedbetween
female hpg andwild-typemicewas that
female hpg mice had significantly less
GFAP in the cerebellum than wild-type
mice.
It is interesting that AD-related
changes were only observed in male,
but not female hpg mice, considering
that a number of previous papers have
observed an increase in A production
and other AD-related changes after
ovariectomy (21, 23, 42). One expla-
nation as to why AD-related changes
were only observed in male hpgmice is
that female mice may have an inher-
ently higher level of neurosteroidogen-
esis, as suggested by the higher P450scc
levels in female mice shown in this
study. In addition to sex steroids in the
blood, sex steroids in thebrainmayalso
cause functional changes; thus future
research is needed to determine
whether there is a gender difference in
other enzymes involved in neurosteroidogenesis in hpg
mice and hence in brain levels of sex steroids. An alterna-
tive or additional explanation is that the AD-associated
changes in male hpg mice were mediated by androgens.
The increased amount ofA42 observed in the hippocam-
pus of male hpgmice supports previous studies that have
shown that androgen depletion by GDX of male animals
increases A, and supplementation with exogenous an-
drogens decreases A levels (17–19, 43–45). The under-
lying mechanism of how androgens modulate A levels is
still under investigation, but it could be via altering the
level of amyloidogenic processing of APP or by altering
degradation of A.
The decreased APP protein, coupled with increased
APP-CTF and PS1 proteins in the hippocampus of male
hpg mice, suggests that depletion of androgens promotes
increased amyloidogenic processing of APP. It is hypoth-
esized that the decreased levels of APP is a consequence of
increased cleavage of APP by BACE into APP-CTF and
that PS1 expression is up-regulated to cleave the higher
amountofAPP-CTF intoA. This hypothesis is supported
by a recent study that found increased testosterone ex-
pression due to knockout of aromatase resulted in de-
FIG. 5. Immunohistochemistry for ChAT in the basal forebrain (A-D). ChAT immunostaining
per neuron was less intense in male hpg mice (A) than in male wild-type (wt) mice (B). A
similar effect was not observed in female brain (C and D). The total number of ChAT-positive
neurons was counted in the caudate/putamen (E) and in the basal forebrain (F). The total
number of ChAT-positive neurons in hpg mice was not significantly different from wt mice of
either gender. Data are shown as mean  SD; scale bar, 50 m
FIG. 6. The concentration of IL-1 (A) and IL-6 (B) in hpg and wild-
type mouse brains. Cytokine levels measured using Luminex in the
whole-brain hemisphere. Data are shown as mean  SEM; *, P  0.05.
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creased APP-CTF and APP intracellular C-terminal do-
main levels, coupled with decreased A42:A40 ratio.
The altered protein levels were attributed to a testoster-
one-mediated decrease in amyloidogenic processing, pri-
marily via decreased BACE expression and activity (44).
Although BACE expression was not measured in the cur-
rent study, results from McAllister et al. correlate well
with the other protein changes observed in this study. Fur-
thermore, testosterone supplementation after GDX re-
sults in decreased PS1 expression in adult mice (46), sup-
porting the results from the current study and suggesting
that androgen depletion may also affect expression of
-secretase in addition to BACE.
It is important to note that some studies have been un-
able to confirm a similar relationship between androgen
depletion and APP or APP-CTF levels (17–19) and have
therefore concluded that androgen depletion does not af-
fect amyloidogenic processing. The findings presented in
this study likely differ from previous results because of the
different hormonal profiles of the mice examined. Previ-
ous studies have used GDX to deplete androgens, which
also results in increased blood levels of LH and FSH. In
contrast, hpg mice have comparably low levels of circu-
lating sex hormones (31) but also low levels of LH and
FSH (30). This may be important because LH is also ca-
pableofpromotingamyloidogenicprocessingandApro-
duction (47, 48). Given this capability, it is possible that
the depletion of LH in male hpgmice was responsible for
the altered levels of proteins related to AD rather than the
depletionof androgens.However, if thiswere the case, one
would expect male hpg mice to be protected against AD-
associated changes and for male and female hpg mice to
showthe samephenotypebecauseboth sexeshad similarly
low LH levels. Therefore, it appears more likely that de-
pleted levels of androgens were responsible for the AD-
associated changes in male hpg mice.
The majority of previous studies have not examined
protein effects that result from androgen depletion in in-
dividual brain regions. Because increased amyloidogenic
processing only occurred in the hippocampus of male hpg
mice, pooling of multiple brain regions would dilute this
effect. Indeed, this was shown to be the case in the current
study because A40 andA42 levels in hpg andwild-type
mice were not significantly different when levels were
measured in the complete brain hemisphere but were sig-
nificantly differentwhen levelswere examined specifically
in the hippocampus. It is interesting that the androgen-
mediated changes in levels of proteins associated with AD
were observed only in the hippocampus and not in other
brain regions. Why the hippocampus is particularly vul-
nerable in AD is still a matter of debate, but the current
results suggest that this may be at least partially mediated
by sex hormones. Estrogen receptor , estrogen receptor
, androgen receptors, and LH receptors are expressed in
the hippocampus (49–51), suggesting that the hippocam-
pus may be highly responsive to sex hormone-mediated
effects. It has been suggested that sex hormones have an
important role in mediating many features of the hip-
pocampus, including hippocampal-dependent cognitive
tasks, synaptic plasticity, and neurogenesis (for review see
Ref. 52). Although only a few studies have compared the
sex hormone-mediated effects in the hippocampus with
other brain regions, it was recently shown that ovariec-
tomy of female rats resulted in decreased expression of an
A-degrading enzyme, insulin-degrading enzyme, specif-
ically in the hippocampus and not in the cerebellum (42),
hence supporting the current results showing that sex hor-
mone-mediated effects on proteins related to AD are
prominent in the hippocampus and not in other brain
regions.
The presence ofwhorls in the thalamus of all agedmice,
regardless of genotype, is interesting, especially consider-
ing that the primary component of thesewhorlswas either
full-length APP or a cleavage product of APP. It may be
premature to describe these structures as amyloid plaques
because rodent A has a different sequence than human
A, and consequently does not generally aggregate and
form amyloid plaques (53). However, it is important to
note that rodent A has been shown to form plaque-like
structures in other animal models (54, 55). The whorls
observed in this study shared similar characteristics with
amyloid plaques; they were composed of aggregated pro-
teins that are immunopositive for bothAPPandPAS stain-
ing, and GFAP-positive processes circled around the
whorls, with some processes entering the whorl itself. It is
not yet known what these whorls are, or why they were
observed specifically in the thalamus and not elsewhere in
the aged mouse brain. Sex hormones did not appear to
affect the number or size of these whorls, suggesting that
this may be a feature of the C3H/J strain or a consequence
of age.
Semiquantitative immunohistochemical analysis sug-
gested a decrease in ChAT staining per neuron in the basal
forebrain ofmale hpgmice comparedwithwild-typemale
mice. This finding supports previous studies that have
shownGDXresults indecreasedChATactivity in themale
rodent brain (56, 57). Furthermore, GDX adult male rats
have lower ChAT intensity per ChAT-positive cell than
sham GDX animals or GDX animals supplemented with
testosterone, similar to what was observed in this study
(58). Interestingly, it has also been shown than testoster-
one depletion does not affect the number of ChAT-posi-
tive cells (59), only the ChAT staining intensity within
cells, suggesting that testosterone depletion does not in-
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duce cell death of ChAT-positive cells but instead down-
regulates ChAT production within neurons. It is still un-
clear how androgens do this, but it is unlikely to be via an
androgen receptor-mediated pathway because only 0.7–
1.1%of cells in the basal forebrain contain both androgen
receptors and ChAT (58). Therefore, the decreased ex-
pression of ChAT observed in male hpgmice was likely to
be due to androgen-mediated effects that were not regu-
lated by androgen receptors. Future studies that quanti-
tatively measure ChAT expression and ChAT enzyme ac-
tivity are needed to confirm the decreased ChAT staining
in hpg male mice observed in this initial study and how
these changes affect acetylcholine levels and cognitive
function in aged hpg mice.
Markers of inflammation were examined in the brains
of hpg mice to see whether circulating sex hormone de-
pletion increased neuroinflammation, as has been sug-
gested to occur in some (60–63), but not all (64–66),
previous studies. Unexpectedly, male hpg mice had a
strong trend for lower levels of IL-1 in the whole-brain
hemisphere compared with wild-type mice, whereas there
was no difference observed between female hpg and fe-
male wild-type mice. There was also no difference in the
amount ofGFAPprotein inmale hpg andwild-type brains
in any brain region. Significantly lower GFAP protein lev-
els were observed in the cerebellum of female hpg mice
than in wild-type mice but not in any other region. These
results do not support those by McQueen et al. (67) who
found higher GFAP protein levels in the CA1 region in the
hippocampus ofmale and female hpgmice, in comparison
with wild-typemice. However, it is important to note that
the earlier study semiquantified GFAP protein expression
by counting the number of immunopositive cells only in
CA1, rather than determining the totalGFAPprotein level
in the whole hippocampus as measured in the current
study. The fact that GFAP protein levels were only signif-
icantly different in the female cerebellummay suggest that
GFAP is primarily regulated by estrogens rather than by
androgens. The current data also do not support a rela-
tionship between sex hormones and apoE levels in males
or females because therewas nodifference in apoEprotein
levels between hpg and wild-type mice of either gender.
This result supports a recent study that found GDX and
subsequent administration of exogenous estradiol or tes-
tosterone did not affect apoE mRNA or protein levels in
themouse brain (68).Overall these results suggest that the
low levels of circulating sex hormones and gonadotropins
in hpgmice do not increase brain inflammation, which in
turn is not a cause or effect of the increased amyloidogenic
processing observed in the male hpg hippocampus.
In conclusion, this study provides evidence for a link
between the depletion of androgens and changes in levels
of proteins related to AD, specifically in the male hip-
pocampus. This study has also revealed that hpgmice are
a novel and potentially useful model for examining the
relationship between long-term sex hormone depletion
and brain changes associated with AD. Although it was
beyond the scope of this study to definitively determine
which individual sex hormone(s) mediated the AD-asso-
ciated changes observed in male hpg mice and the under-
lying mechanism of androgen-mediated effects, these
promising findings warrant future studies using hpgmice
to examine pathology associated with AD.
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